Humacyte posts Q1 net income $39.1M; Symvess launch generates $147K revenue

Humacyte, Inc.

2025-Q1 EPS reported $0.28 revenue$517,000

Q1 2025 revenue $517K ($147K from first Symvess commercial sales); no revenue in Q1 2024.
Net income of $39.1M vs net loss of $31.9M YoY, driven by $62.3M non-cash remeasurement gain.
Cash and equivalents $113.2M; $46.7M net from March public offering extended runway.
Reduced workforce by ~31 employees; expects net savings of $13.8M in 2025, over $50M by 2026.
45 hospitals initiated Symvess VAC approval; 5 approved. On track for dialysis BLA in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.